News emerged at midday on November 15. Yesterday, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List" (2026 edition).
Among the inclusions, Simcere Pharmaceutical's innovative stroke drug Xianbixin sublingual tablets (edaravone and dexborneol sublingual tablets) were added to medical insurance for the first time; Xianbixin injection successfully completed its third medical insurance renewal, with a price reduction of 12%. The dual benefits of "new formulation inclusion plus old product renewal" will significantly reduce the medication burden for patients with acute ischemic stroke and promote the widespread adoption of innovative brain cytoprotective treatment regimens across medical institutions at all levels nationwide.
Stroke is known for its high incidence and high disability rates, with acute ischemic stroke accounting for more than 85% of all strokes. For these patients, early brain cytoprotection is key to reducing the risk of disability. The Xianbixin series products are dual-target brain cytoprotective agents containing two active ingredients, edaravone and dexborneol, which exert synergistic antioxidant and anti-inflammatory effects and can significantly reduce neurological impairment caused by acute ischemic stroke. Studies show that continuous 14-day treatment with Xianbixin can significantly increase the proportion of patients achieving functional independence at 90 days and reduce the risk of disability.
In terms of clinical application scenarios, Xianbixin injection and sublingual tablets complement and connect with each other. Xianbixin injection mainly focuses on standardized acute-phase treatment within hospitals, providing strong support for in-hospital emergency care; while Xianbixin sublingual tablets, with their unique fast-disintegrating sublingual formulation, successfully extend the treatment scenario to post-discharge and home rehabilitation. Simcere Pharmaceutical President Zhou Yunshu stated: "Since the launch of Xianbixin injection and sublingual tablets, they have helped more than 8 million stroke patients. The inclusion of Xianbixin sublingual tablets in the national medical insurance list this time is a key step in bridging the 'last mile' of innovative drug accessibility. We will take this opportunity to actively cooperate with the implementation of medical insurance policies in various regions, so that more stroke patients can access and afford cutting-edge innovative drugs during the golden treatment window and subsequent rehabilitation period. In the future, Simcere Pharmaceutical will continue to focus on major disease areas such as neuroscience, using more high-quality innovative achievements to support the 'Healthy China 2030' plan."